NrlHM2
Second macin-family antimicrobial peptide candidate from Hirudo medicinalis (Serebrennikova 2025) — paralog of NrlHM1.
Preclinical / mechanisticLast updated: 2026-05-27 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Second macin-family antimicrobial peptide candidate from Hirudo medicinalis (Serebrennikova 2025) — paralog of NrlHM1.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Antibiotic stewardship
Clinical translation limit
NrlHM2's in vitro antibacterial activity does NOT establish clinical efficacy. No FDA-approved derivative exists; functional differentiation from NrlHM1 remains undefined.
Molecular Profile
- Category
- Antimicrobial
- Evidence tier
- Preclinical
- Molecular weight
- 8,500 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2025 · Serebrennikova M et al.
Biological Targets
- → Gram-positive bacteria (laboratory strains)
Key Citations
- Serebrennikova M et al. (2025), Int J Mol Sci · PMID 40725149
External Resources
Related Antimicrobial Compounds
Theromacin
Antimicrobial peptide active against Gram-negative bacteria — innate immunity of leech.
Theromyzin
Antimicrobial peptide; structural analogue of mammalian defensin family.
Macrostomin
Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.
Hirunipins
Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.